Amgen Announces Top-Line Data From Remicade Biosimilar Study

Amgen, Inc. announced positive top-line results from a late-stage study evaluating the safety and efficacy of ABP 710, its biosimilar version of J&J/Merck’s Remicade, compared to the reference product for the treatment of moderate-to-severe rheumatoid arthritis (RA). ABP 710 is an anti-TNF monoclonal antibody.